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abstract
Current prophylactic and hygienic measures notwithstanding, implant-related infection remains among leading 
reasons for failure in orthopaedics and trauma surgery, resulting in extremely high social and economic costs. Various 
antibacterial coating technologies have been proven safe and effective both in preclinical and in clinical settings and 
able to reduce post-surgical infections up to 90%, depending on the type of the coating and on the experimental setup. 
In spite of this findings, the widespread use of these technologies is still limited by several factors. After reviewing 
the latest evidence on currently available antibacterial coatings, an algorithm is proposed to calculate the impact 
of the delayed introduction of these technologies in the clinical practice. When applied to joint arthroplasties, our 
calculator shows that each year of delay to implement an antibacterial coating, able to reduce post-surgical infection 
by 80% at a final user’s cost price of €600, causes an estimated 35 200 new cases of periprosthetic joint infection in 
Europe and additional annual hospital costs of approximately €440 million. Faster and more affordable regulatory 
pathways for antibacterial coating technologies and an adequate reimbursement policy for their clinical use appear a 
feasible solution to mitigate the impact of implant-related infections and may benefit patients, healthcare systems, 
and related research.
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реферат
несмотря на современные достижения профилактики и гигиены, имплант-ассоциированная инфекция 
остается одной из основных причин несостоятельных результатов ортопедических и травматологических 
вмешательств, что приводит к чрезвычайно высоким социальным и экономическим издержкам. Различные 
технологии антибактериального покрытия имплантатов зарекомендовали себя как безопасное и эффектив-
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relevance 
Approximately 2 million joint arthroplasties are 
performed annually in Europe [1], while osteosynthe-
sis for long bone fractures shows similar figures [2].
undoubtedly, these numbers reflect the high success of 
biomaterials and related technologies in orthopedics 
and trauma in the last decades. However, even if the 
routine use of biomaterials has been pivotal in reduc-
ing the burden of disability worldwide, the long-term 
durability of implants is not guaranteed, and infection 
remains one of the main reasons for failure. In fact, 
considering high risk and oncological cases, peripros-
thetic joint infection (PJI) affects between 0.5% and 
15% of patients undergoing primary or revision joint 
arthroplasty [3, 4]. Similarly, surgical site infection 
(SSI) after internal osteosynthesis for closed fracture 
has a reported incidence ranging from 0.5% to 10% 
[5, 6, 7, 8], and up to 50% after open fractures [9]. 
In line with this figures, SSI following spine surgery 
occurs in 1% to 14% of patients, depending on the pre-
operative diagnosis and type of surgery [10, 11].
The economic and social costs of implant-related 
infections are significant [12, 13, 14, 15], with high 
morbidity and a possible increase in mortality [6], 
In particular, direct hospital costs, related to the 
mana gement of PJI, range from approximately 
€ 20 000 to € 60 000, while the long-term economic 
effect of post-surgical infection after joint arthro-
plasty has been calculated to exceed uS$ 390 000 per 
case [16, 17, 18,19, 20, 21, 22, 23, 24].
rationale for local antibacterial implant 
protection
Whenever a biomaterial is implanted, a competi-
tion for surface colonization starts between the host’s 
and the bacterial cells, that may eventually be pre-
sent. Whenever the bacteria adhere to the implant, 
immediate biofilm formation takes place, making the 
micro organisms extremely resistant to host’s defense 
mechanisms and to antimicrobials [25, 26, 27, 28, 29]. 
The colonization of the implant from the bacteria is 
then decided at the very time of surgery, even if the 
clinical consequences, the “post-surgical infection”, 
may become evident only weeks, months or even years 
after surgery, depending on the relative balance bet-
ween the microorganisms and the host’s individual 
inflammatory response. 
This observation grounds the basis for protecting 
the implant at the very time of surgery with surface 
finishing or coatings specifically designed to selective-
ly prevent bacterial adhesion and biofilm formation, 
without interfering with the biocompatibility and the 
long-term duration and function of the implant [30]. 
Various technologies have been investigated in the 
last decades and can be classified according to their 
mechanism of action as follows [31] (Table 1):
– Passive surface finishing/modification: this 
approach aims at preventing or reducing bacterial ad-
hesion to implants through surface chemistry and/or 
physical modifications, without the use of any phar-
macologically active substance. Examples of this ap-
proach include modified titanium dioxide surface or 
polymer coatings.
– Active surface finishing/modification: pharma-
cologically active pre-incorporated bactericidal agents, 
such as antibiotics, antiseptics, metal ions, or other or-
ganic and inorganic substances, are actively released 
from the implant in order to reduce bacterial adhesion. 
Examples of this approach are “contact killing” active 
surface with silver- or iodine-coated joint implants.
– Local carriers or coatings: this strategy employs 
local antibacterial carriers, or coatings, that are not 
built into the device, but rather are applied during sur-
gery, immediately prior to the insertion of the implant. 
They may have direct or synergistic antibacterial/anti-
adhesive activity or may deliver high local concentra-
tions of loaded antibiotics or antibacterial agents.
ное решение проблемы инфицирования в процессе как доклинических исследований, так и в клинической 
практике, что способствует снижению частоты послеоперационной инфекции до 90% в зависимости от типа 
покрытия и условий использования. несмотря на такие выводы, широкое внедрение подобных техноло-
гий по-прежнему ограничено несколькими факторами. Изучив наиболее актуальные данные по доступным 
антибактериальным покрытиям, авторы предлагают алгоритм для расчета влияния несвоевременного вне-
дрения таких технологий в клиническую практику. Применение предлагаемого калькулятора к операциям 
по эндопротезированию суставов демонстрирует, что каждый год отсрочки внедрения антибактериальных 
покрытий, который позволил бы снизить частоту послеоперационной инфекции на 80% при стоимости для 
конечного пользователя в размере 600 евро, приведет примерно к 35 200 новых случаев возникновения пери-
протезной инфекции в странах Европы и к дополнительным ежегодным госпитальным расходам в размере 
около 440 млн евро. ускоренные и более доступные с точки зрения затрат процессы нормативного регулиро-
вания в отношении технологий антибактериального покрытия имплантатов, а также адекватная политика 
возмещения расходов по клиническому использованию таких технологий представляются возможным реше-
нием для снижения частоты имплант-ассоциированной инфекции, улучшения качества лечения пациентов, 
снижения нагрузки на систему здравоохранения и для стимулирования научных изысканий. 
Ключевые слова: эндопротезирование, имплантаты, антибактериальное покрытие, перипротезная  
инфекция, расходы на лечение. 
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Table 1
Classification of antibacterial implant protection strategies [31]
Features/examples Development stage
Passive Surface/Finishing Modifications (PSM)
Prevention of bacterial adhesion
   Hydrophilic surface Preclinical
   Superhydrophobic surface Preclinical
   Anti-adhesive polymers Preclinical
   Nanopatterned surface Preclinical
   Albumin Preclinical
   Hydrogels Preclinical
   Biosurfactants Preclinical
Active Surface/Finishing Modifications (ASM)
Inorganic
   silver ions and nanoparticles Market
   other metals (copper, zinc, titanium dioxide, etc.) Preclinical
   non-metals: iodine Clinical
   other non-metal ions (selenium, graphene, etc.) Preclinical
Organic
   coated/linked antibiotics Market
   covalently linked antibiotics Preclinical
   antimicrobial peptides Preclinical
   cytokines Preclinical
   enzymes and biofilm-disrupting agents Preclinical
   chitosan derivatives Preclinical
Synthetic
   non-antibiotic antimicrobial compounds Preclinical
  “smart” coatings Preclinical
Combined
   multilayer coating Preclinical
Local Carriers or Coatings (LCC)
Non-biodegradable
   antibiotic-loaded poly (methyl methacrylate) Market
Biodegradable
   antibiotic-loaded bone grafts and substitutes Market
   fast-resorbable hydrogel (acting both as passive surface modification system  
and as local antibiotic carrier)
Market
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In spite of several products found effective at a re-
search level, translating preclinical findings into clini-
cal practice appears particularly challenging, time-
consuming, and expensive. As a result, many promising 
coating technologies fail to reach the market due to 
regulatory, commercial or economic restrictions, with 
a loss of chance for the patients and for the health care 
systems, which is difficult to quantify [32].
antibacterial coating of implants:  
current technologies
Besides antibiotic-loaded poly(methyl methacry-
late) (PMMA), bone grafts, and calcium-based bone 
substitutes that, even if adopted in the clinical set-
ting, were not specifically designed to act as antimi-
crobial coatings of implants, only four technologies 
are currently available in orthopedics and trauma for 
clinical use, or at least with reported clinical results 
[33]. These include silver and iodine coatings, gen-
tamicin poly(D, L-lactide) (PLLA) coating, and a fast-
resorbable hydrogel coating composed of covalently 
linked hyaluronan and PLLA (Defensive Antibacterial 
Coating (DAC®); Novagenit Srl, Mezzolombardo, Italy) 
(Table 2).
silver coatings
Silver antibacterial activity is known since ancient 
ages. Silver dissolved cations are capable of interfer-
ing with bacterial cell membrane permeability and 
cellular metabolism and, when released in an aque-
ous medium, contribute to the formation of reactive 
oxygen species that potentially influence prokaryotic 
cells [33]. Different technologies are currently used 
to apply the silver coating to metallic orthopaedic 
implants [33, 34, 35]. Comparative and prospective 
studies are not available and only retrospective case 
series have been published, with coating application 
restricted to tumour prostheses [36, 37]. 
Wafa et al. [38] reported the results of silver-coat-
ed tumour prostheses in 85 patients compared with 
85 matched control patients. Indications included 
50 primary reconstructions (29.4%), 79 one-stage revi-
sions (46.5%), and 41 two-stage revisions for infection 
(24.1%). At a minimum follow-up of 12 months, there 
was a significant reduction in the overall postopera-
tive infection rate from 22.4% to 11.8% (p = 0.03) in 
favour of the silver-coated implant group, with a mean 
reduction of approximately 48% in infection rate.
Table 2
Comparison of clinically available antimicrobial coating technologies, specifically designed  
for orthopaedics and trauma implants
Technology Regulatory phase
Trademark and manufacture 
company
Mechanism  
of action Main applications
Silver Market Agluna® (Accentus Medical Ltd, 
Didcot, united Kingdom); Mutars® 
(Implantcast GmbH, Buxtehude, 
Germany); PorAg (Waldemar 
Link GmbH & Co. KG, Hamburg, 
Germany)
Silver ion 
release
Tumour 
mega-prosthesis
Iodine Clinical 
trials
Not applicable Iodine release Titanium implants 
including spine 
instrumentation, 
hip and knee joint 
arthroplasties, plates 
and screws
Gentamicin 
poly(D, 
L-lactide) matrix
Market uTN PROtect Tibial Nail® (DePuy 
Synthes, Bettlach, Switzerland); 
Expert Tibial Nail (ETN) PROtect® 
(DePuy Synthes, Johnson & 
Johnson, New Brunswick, New 
Jersey)
Gentamicin 
release
Tibial nail  
for the treatment  
of tibial fractures  
and nonunions
Hyaluronic acid 
and poly(D, 
L-lactide) 
hydrogel
Market Defensive Antibacterial 
Coating (DAC®) (Novagenit Srl, 
Mezzolombardo, Italy)
Antifouling 
activity with 
ancillary 
antibiotic 
release
Orthopaedics, 
traumatology, 
dentistry, and 
maxillofacial 
implants
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The routine use of silver-coated implants remains 
rather limited for several reasons, including possible 
toxicity of silver ions [39], and incomplete protection 
of the implant, since the intramedullary part of the 
prosthesis and some modular components cannot be 
coated. Moreover, only a few implant designs are of-
fered with silver coating protection, while the cost of 
the technology remains quite high when considering 
applications outside oncology [40].
iodine coating
Povidone-iodine can be used as an electrolyte, re-
sulting in the formation of an adhesive, porous an-
odic oxide with the antiseptic properties of iodine 
[41]. Besides extensive preclinical studies [41, 42, 43], 
excellent clinical efficacy was reported for iodine 
coating of titanium alloys in a continuous, non-
comparative series of 222 patients [44]. Preoperative 
diagnoses included tumour in 95 cases (42.8%), 
34 limb deformities (15.3%), 29 cases of degen-
erative disease (13.1%), 27 osteomyelitis (12.2%), 
24 nonunions (10.8%), and 16 fractures (7.2%). A va-
riety of implants were used: 82 spinal instrumenta-
tions, 55 plates for osteosynthesis, 36 external fixa-
tions (pins and wires), 32 tumour prostheses, ten hip 
prostheses, four knee prostheses, two nails, and one 
cannulated screw. At a mean follow-up of 18.4 months 
(3 to 44), acute infection developed in three tumour 
cases (1.9%).
Two more recent non-comparative studies — one 
investigating iodine coating and megaprosthesis [45], 
the other investigating total hip arthroplasty (THA)
[46] — confirmed the safety and efficacy of the tech-
nology at longer follow-ups. Based on these find-
ings, clinical trials are currently ongoing to meet the 
regulatory requirements for market approval (Fig. 1). 
While no adverse event has been reported to date, the 
longer-term effects of local application of iodine coat-
ing and the application to materials other than tita-
nium are yet to be assessed.
Fig. 1. Male, 63 years old. Late periprosthetic joint infection:
a — preoperative X-ray examination;
b — second failed antibiotic-loaded spacer; persistence  
of infection; preoperative X-ray examination; 
с —  cementless iodine-coated hip prosthesis; intra-operative pictures;
d — two years after surgery; the patient is infection free;  
c-reactive protein: 1 mg/l; no radiographic signs of implant loosening
а b
с
d
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gentamicin plla coating
A coating for tibial nails, composed of a poly-l-
lactic acid (PLLA) matrix, loaded with gentamicin, 
was first introduced into clinical use in Europe ap-
proximately fifteen years ago. The coating provides 
80% release of the antibiotic within the first 48 hours 
[47]. In the first published clinical report, Fuchs et 
al. [48] observed no deep infections at six months’ 
follow-up in 21 patients treated with a uTN PROtect 
Tibial Nail (DePuy Synthes, Bettlach, Switzerland) 
for closed or open tibial fractures, as well as for revi-
sions. Metsemakers et al. [49] reported a retrospec-
tive analysis, including nine patients with a Gustilo 
and Anderson grade II or grade III open tibial frac-
ture, four infected nonunions, two acute tibial shaft 
fractures pretreated with external fixation, and 
one aseptic nonunion with a soft tissue defect. At 
18 months’ follow-up, no implant-associated deep 
infection was reported. Finally, in the most recent 
and largest study, data from four centres, analyzed 
the outcome of 99 patients with fresh open or closed 
tibial fractures or undergoing nonunion revision sur-
gery [50]. At 18 months’ follow-up, deep surgical site 
infection or osteomyelitis was noted in 4/55 patients 
(7.2%) after fresh fracture and in 2/26 patients (7.7%) 
after revision surgery. The heterogeneous material 
and the lack of a comparator makes the interpreta-
tion of these results particularly difficult.
Apart from the absence of comparative trials, a 
limit of this technology is the fact that it is only avail-
able for the tibia and for one specific nail design. 
Furthermore, screws and fixation holes are not pro-
tected by the coating, while gentamicin resistance, 
ranging from 2% to 50% in Europe [51], may reduce 
the efficacy of the coating in some cases.
d.a.c. hydrogel
The Defensive Antibacterial Coating (D.A.C.) hy-
drogel is the first antimicrobial coating specifically 
designed to protect a variety of biomaterials in or-
thopedics, traumatology, dentistry, and maxillofacial 
surgery [52, 53]. The device is based on the ability of 
hyaluronic-based compounds to reduce bacterial ad-
hesion and biofilm formation, and to protect against 
various infectious agents [54, 55, 56]. Although de-
signed as a stand-alone product, the DAC hydrogel 
is capable of entrapping several antibacterial agents 
at concentrations ranging from 2% to 10%, released 
locally for up to 72 hours, with an amount of drug re-
leased that is hundreds or thousands of times higher 
than the minimum inhibitory concentration (MIC), 
in a time- and dose-dependent manner [52]. This 
is why, according to the classification mentioned 
earlier, the DAC hydrogel features and intermedi-
ate mechanism of action and can both be classified 
as a Passive Surface Modification and as a Local 
Antibiotic Carrier.
The safety and efficacy of DAC hydrogel have 
been tested in several preclinical in vitro and in vivo 
studies [57, 58, 59]. Clinically, a first multicenter, ran-
domized prospective trial was conducted in Europe, 
on a total of 380 patients, scheduled to undergo pri-
mary or revision hip or knee joint arthroplasty [60]. 
Overall, 373 patients were available at a mean follow-
up of 14.5 months (sd 5.5). A total of 11 SSIs were ob-
served in the control group, with only one observed 
in the treatment group (6% vs 0.6%; p = 0.003). No lo-
cal or systemic side effects related to the DAC hydro-
gel coating were reported, and no detectable inter-
ference with implant osteointegration was noted. In 
another multicentre prospective study, 256 patients 
undergoing osteosynthesis for a closed fracture were 
randomly assigned to receive the antibiotic-loaded 
DAC coating or to a control group without coating. 
At a mean follow-up of 18.1 months (sd 4.5), six SSIs 
(4.6%) were observed in the control group compared 
with none in the treated group (p<0.02). No local or 
systemic side effects related to DAC hydrogel coating 
were observed, and no detectable interference with 
bone healing was reported [61]. More recently, DAC 
hydrogel-coated cementless was tested safe for one-
stage exchange for infected prosthesis (Fig. 2) [62]. 
However, longer-term data are required to examine 
delayed or late prosthetic joint infections. In fact, 
while the quick resorption of the hydrogel makes 
long-term side effects quite unlikely, this same fea-
ture may limit or prevent the ability of this technol-
ogy to protect the implant from late, haematogenous 
infections. 
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potential impact of large-scale  
application of antibacterial coatings
Implementing measures against post-surgical in-
fection after joint arthroplasty may result in a meas-
urable reduction of PJI, with significant cost saving 
and improved quality of life. 
According to Graves et al. [63], considering a co-
hort of 77 321 patients undergoing primary total hip 
replacement in the united Kingdom, a combined 
treatment strategy able to reduce post-surgical infec-
tion (odds ratio 0.13) may prevent 1481 cases of deep 
infection, leading to annual cost savings of £8 325 277, 
when compared with a baseline strategy (plain ce-
ment, conventional ventilation, and no systemic 
antibiotics). 
Shearer et al. [64] calculated that the net monetary 
benefit resulting from a 10% reduction in PJIs was 
$278 per index procedure and concluded that strate-
gies aimed at reducing PJI may have a greater effect 
on cost and long-term effectiveness of THA than fur-
ther enhancements in implant longevity. 
Our group recently proposed an algorithm to 
calculate the cost-effectiveness of different anti-
bacterial coating strategies applied to joint pros-
theses, taking both direct and indirect hospital 
costs into account [40]. According to this model, 
an antibacterial coating technology able to reduce 
post-surgical infection by 80%, at a cost per pa-
tient of €600, would provide a reduction in hospital 
costs of €200 per patient if routinely applied in a 
population that would otherwise have an expected 
post-surgical infection rate of 2%. Projecting these 
figures at a European level, with approximately 
2.2 million joint arthroplasties performed per year, 
we may speculate that a year of delay in the rou-
tine use of such a coating would result in 35 200 
additional PJI cases per year with additional an-
nual costs of approximately € 440 million per year 
(Table 3 and 4) [65]. These calculations do not in-
clude any costs that might result from an increased 
mortality rate, permanent disability deriving from 
post-surgical infection, or medicolegal claims.
Fig. 2. Male, 82 years old. Delayed periprosthetic knee infection. Failed debridement and irrigation  
and prolonged suppressive antibiotic therapy. Multi-resistant Staph. Aureus. Joint instability due to severe medial 
ligaments insufficiency:
a — pre-operative X-ray examination;
b — intra-operative picture, at the time of “one-stage” knee revision surgery; based on pre-operative antibiogram, 
tigecycline-loaded Defensive Antibacterial Coating hydrogel is applied on the cementless stem of the revision implant;
c — radiographic control, two years after surgery; no sign of osteolysis or loosening;
d — clinical images at two years from revision surgery; no signs of infection recurrence and full function recovery;  
the patient has just been operated on the contralateral knee for osteoarthritis
а b
с d
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Тable 4
Simulation of the algorithm application to a cohort of 2.2 million patients, approximately  
equivalent to the number of total joint replacements performed each year in Europe.  
According to this scenario, the routine use of the coating would be associated to annual costs  
savings of €440 000 000 and 8000 new cases of PJI, compared to 44 000 new cases  
of PJI if the coating is not used
  No coating  ABC
Joint arthroplasty, average cost per patient €8 000
Joint arthroplasties per year, number 2 200 000
Total cost of joint arthroplasties per year €17 600 000 000
ABC cost per patient €0 €600
% of expected PJI (without the coating) 2,0
% reduction of PJI with ABC 80
Expected infections, number 44 000,0  8 800,0
PJI treatment, cost per case €50 000
Costs per all septic complication treatment €2 200 000 000  €440 000 000
Costs for joint arthroplasty including septic complications €19 800 000 000 €18 040 000 000
Total costs for ABC   €1 320 000 000
Total costs €19 800 000 000 €19 360 000 000
Balance + €440 000 000 
% Balance (Total costs with ABC/without) 97,8
ABC — antibacterial coating; PJI — prosthetic joint infection.
Table 3
Algorithm to calculate the economic impact of an antibacterial coating of joint arthroplasty;  
a positive balance indicates that, for the selected parameters, the ABC technology is associated  
with a net cost saving, a negative value would indicate a net economic loss [40]  
  No coating ABC
Joint replacement, average cost per patient a
Joint arthroplasties per year, n b
Total cost of joint arthroplasties per year c = a*b
ABC cost per patient 0 d
% of expected PJI e
% reduction of PJI with ABC f
Expected infections, n g = b*(e/100) h = b*(e/100)*(1-f/100)
PJI treatment, cost per case i
Costs per all septic complication treatment k = g*i l = h*i
Costs for joint arthroplasty including septic complications m = c+k n = c+l
Total costs for ABC   o = b*d
Total costs p = m q = n+o
Balance r = p-q
% Balance (Total costs with ABC/without) r´ = q/p 
ABC — antibacterial coating; PJI — prosthetic joint infection.
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conclusions
Implant-related infections in orthopedics and 
trauma have a tremendous social and economic im-
pact projected to grow over the next decades and as-
sociated with increased rates of morbidity and mortal-
ity. Despite the recognized need for implant-related 
infection containment and the demonstrated efficacy 
of some antibacterial coatings notwithstanding, only 
a few technologies are currently available in ortho-
paedics and trauma.
Given the potential benefits that can be antici-
pated scientifically by a wider application of an-
tibacterial implant coating technologies, in our 
opinion, any effort should be made to increase the 
awareness of health care providers and their patients 
concerning the existing technologies and their pos-
sible contribution to mitigate septic complication; 
furthermore, specific reimbursements for the cur-
rently available coatings should be introduced, with 
faster and more affordable regulatory pathways for 
the most promising technologies in the pipeline. 
At the same time, an efficient and independent 
post-marketing surveillance system need to be set 
at national or international level, in order to moni-
tor the clinical results and promptly report on any 
possible side effect or long-term complication 
of such new technologies.
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